<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">The same de-escalation plan makes provision for the distribution of anti-retroviral medication (ARVs) to the 5 million South Africans currently on ARVs [
 <xref ref-type="bibr" rid="CR1">1</xref>]. While there is no evidence that people living with HIV (PLHIV) who are virally suppressed on ARVs are at increased risk of severe COVID-19 disease, there is genuine concern that PLHIV with advanced immunocompromise or unsuppressed HIV may suffer worse COVID-19 outcomes [
 <xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, there is extra pressure in South Africa to decrease the exposure of PLHIV to COVID-19 infection and rapidly increase viral suppression rates.
</p>
